OBJECTIVE: The primary objective of this article is to review the literature regarding the speed of response to antidepressant drugs and potential strategies to accelerate the antidepressant response in new antidepressant-free patients with depression. Based on these data, we try to propose both an effective and safe antidepressant treatment strategy to alleviate depressive symptoms at the earliest opportunity. DATA SOURCES: Data were identified by searches of Medline (1966 to September 2009) and references from relevant articles and books. Search terms included depression, antidepressant, predictor, response, onset, acceleration, and augmentation. As our focus was on the acute phase treatment of depression, articles relevant to treatment-resistant depression were excluded. Only articles written in English or Japanese were consulted. DATA SELECTION: Studies, reviews, and books pertaining to the treatment of depression with a special regard to accelerating therapeutic effects were selected. DATA SYNTHESIS: Most of the available treatment guidelines for major depressive disorders recommend the continuous use of antidepressants for 4 to 8 weeks based on the idea of a delayed onset of response to these drugs. Contrary to this conventional belief, the recent data indicate that antidepressants start to exert their effects within 2 weeks and early non-response could predict a subsequent unfavorable outcome. CONCLUSIONS: These findings suggest the need of revisiting the timing of an antidepressant switch for early non-responders, whereby switching could be commenced in as early as 2 weeks. Copyright 2009 Elsevier B.V. All rights reserved.
OBJECTIVE: The primary objective of this article is to review the literature regarding the speed of response to antidepressant drugs and potential strategies to accelerate the antidepressant response in new antidepressant-free patients with depression. Based on these data, we try to propose both an effective and safe antidepressant treatment strategy to alleviate depressive symptoms at the earliest opportunity. DATA SOURCES: Data were identified by searches of Medline (1966 to September 2009) and references from relevant articles and books. Search terms included depression, antidepressant, predictor, response, onset, acceleration, and augmentation. As our focus was on the acute phase treatment of depression, articles relevant to treatment-resistant depression were excluded. Only articles written in English or Japanese were consulted. DATA SELECTION: Studies, reviews, and books pertaining to the treatment of depression with a special regard to accelerating therapeutic effects were selected. DATA SYNTHESIS: Most of the available treatment guidelines for major depressive disorders recommend the continuous use of antidepressants for 4 to 8 weeks based on the idea of a delayed onset of response to these drugs. Contrary to this conventional belief, the recent data indicate that antidepressants start to exert their effects within 2 weeks and early non-response could predict a subsequent unfavorable outcome. CONCLUSIONS: These findings suggest the need of revisiting the timing of an antidepressant switch for early non-responders, whereby switching could be commenced in as early as 2 weeks. Copyright 2009 Elsevier B.V. All rights reserved.
Authors: Stella Bitran; Amy H Farabaugh; Victoria E Ameral; Rachel A LaRocca; Alisabet J Clain; Maurizio Fava; David Mischoulon Journal: Int Clin Psychopharmacol Date: 2011-07 Impact factor: 1.659
Authors: Francis L Pazini; Mauricio P Cunha; Dayane Azevedo; Julia M Rosa; André Colla; Jade de Oliveira; Ana B Ramos-Hryb; Patricia S Brocardo; Joana Gil-Mohapel; Ana Lúcia S Rodrigues Journal: Mol Neurobiol Date: 2016-10-06 Impact factor: 5.590
Authors: Belinda Graham; Natalia M Garcia; Mark S Burton; Andrew A Cooper; Peter P Roy-Byrne; Matig R Mavissakalian; Norah C Feeny; Lori A Zoellner Journal: Br J Psychiatry Date: 2018-10-25 Impact factor: 9.319
Authors: Daniel E Casey; Kimberly K Laubmeier; Sabrina Vogel Marler; Robert A Forbes; Ross A Baker Journal: Prim Care Companion CNS Disord Date: 2012-05-31
Authors: Luis Molina; Byron Recinos; Bezner Paz; Mauricio Rovelo; Fanny Elizabeth Elias Rodriguez; José Calderón; Arturo Arellano; Santiago Pomata; María Verónica Rey; Santiago Perez-Lloret Journal: Clin Drug Investig Date: 2016-06 Impact factor: 2.859
Authors: Francis L Pazini; Mauricio P Cunha; Julia M Rosa; André R S Colla; Vicente Lieberknecht; Ágatha Oliveira; Ana Lúcia S Rodrigues Journal: Mol Neurobiol Date: 2015-12-11 Impact factor: 5.590